Macranthoside B

Synonyms: 灰毡毛忍冬次皂苷乙
Macranthoside B 是一种具有体外和体内抗癌活性的细胞凋亡 (apoptosis) 诱导剂,可诱导癌细胞发生自噬 (autophagy) 和铁死亡 (ferroptosis),并可通过诱导细胞内 ROS 积累、激活 AMPK、抑制 mTOR 和 P70S6 激酶的磷酸化以及调控 Bcl-2/Bax 的表达,激活 caspase-3、caspase-9 及内源性半胱天冬酶级联反应,诱导 PARP 裂解/降解,抑制 NRF2 信号通路,并通过 NCOA4 依赖的铁蛋白自噬破坏铁稳态,上调 Lip-ROS,降低线粒体膜电位,激活 JNK 通路,从而用于卵巢癌、肝癌、胃癌、乳腺癌、结肠癌、胶质瘤、黑色素瘤、食管胃结合部腺癌及宫颈癌的研究。
产品编号: MS-H83466 纯度: 99.95% CAS No.: 146100-02-9 分子式: C53H86O22 分子量: 1075.24
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Macranthoside B 是一种具有体外和体内抗癌活性的细胞凋亡 (apoptosis) 诱导剂,可诱导癌细胞发生自噬 (autophagy) 和铁死亡 (ferroptosis),并可通过诱导细胞内 ROS 积累、激活 AMPK、抑制 mTOR 和 P70S6 激酶的磷酸化以及调控 Bcl-2/Bax 的表达,激活 caspase-3、caspase-9 及内源性半胱天冬酶级联反应,诱导 PARP 裂解/降解,抑制 NRF2 信号通路,并通过 NCOA4 依赖的铁蛋白自噬破坏铁稳态,上调 Lip-ROS,降低线粒体膜电位,激活 JNK 通路,从而用于卵巢癌、肝癌、胃癌、乳腺癌、结肠癌、胶质瘤、黑色素瘤、食管胃结合部腺癌及宫颈癌的研究。

生物实验数据

生物活性 Macranthoside B is an apoptosis inducer with in vitro and in vivo anticancer activity that induces autophagy and ferroptosis in cancer cells and, by inducing intracellular ROS accumulation, activating AMPK, inhibiting the phosphorylation of mTOR and P70S6 kinase, and regulating Bcl-2/Bax expression, activates caspase-3, caspase-9, and the intrinsic caspase cascade, induces PARP cleavage/degradation, inhibits the NRF2 signaling pathway, and disrupts iron homeostasis through NCOA4-dependent ferritinophagy, upregulates Lip-ROS, reduces mitochondrial membrane potential, and activates the JNK pathway, thereby being useful for research on ovarian cancer, liver cancer, gastric cancer, breast cancer, colon cancer, glioma, melanoma, esophagogastric junction adenocarcinoma, and cervical cancer.
IC50 & Target

mTOR

 

AMPK

 

Caspase-9

 

Caspase 3

 

Bcl-2

 

Bax

 

体外研究
(In Vitro)

Macranthoside B (1.25-20 μM; 24-72 h) 可呈时间和浓度依赖性抑制人卵巢癌 A2780 细胞增殖,其 IC50 值介于 7.52 μM 至 14.66 μM 之间,且对人正常胚胎肺成纤维细胞 HFL1 的细胞毒性较低。
Macranthoside B (5-20 μM; 6 h treatment, followed by 15 days of growth) 可呈剂量依赖性抑制人卵巢癌 A2780 细胞的克隆形成能力,其 IC50 为 8.46 μM。
Macranthoside B (5-20 μM; 48 h) 可呈剂量依赖性地激活人卵巢癌 A2780 细胞中的 AMPK 并抑制 mTOR/P70S6K 通路。
Macranthoside B (2.55-80 μM; 48 h) 可在体外强效抑制人源 HepG2、MGC-803、MCF-7、SW1116、U251,大鼠源 C6 以及小鼠源 B16F1、B16F10 癌细胞的增殖,其 IC50 值介于 10 μM 至 18 μM 之间。
Macranthoside B (0-40 μM; 24, 48 h) 以浓度依赖方式抑制 SKGT-4、OE-19 和 OE-33 这三种 AEG 细胞的活力,其作用 48 h 的 IC50 值介于 4.74 至 8.59 μM 之间,且对正常 NGEC 细胞的活性较弱。
Macranthoside B (8-10 μM; 24 h) 可呈浓度依赖性抑制 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞的集落形成能力,在 8 μM 和 10 μM 浓度下可产生显著抑制作用。
Macranthoside B (10-15 μM; 48 h) 以浓度依赖的方式抑制 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞的增殖,在 10 μM 和 15 μM 浓度下 EDU 阳性细胞数量显著减少。
Macranthoside B (8-10 μM; 36 h) 可呈浓度依赖性抑制 SKGT-4 和 OE-19 型食管胃结合部腺癌 (AEG) 细胞的迁移与侵袭,在 8 μM 和 10 μM 浓度下抑制作用显著。
Macranthoside B (5-20 μM; 24-48 h) 可呈剂量依赖性诱导人卵巢癌 A2780 细胞凋亡,而自噬抑制剂 3-Methyladenine (MS-H80278) 或泛半胱天冬酶抑制剂 Z-VAD-FMK (MS-L66221) 的预处理可减弱该凋亡效应。
Macranthoside B (5-20 μM; 48 h) 可呈剂量依赖性上调人卵巢癌 A2780 细胞中的促凋亡标志物 (活化的 caspase-3、活化的 caspase-9、活化的 PARP) 和自噬标志物 LC3-II;抑制自噬会降低细胞凋亡水平,而抑制凋亡则会增强自噬,抑制 ROS 或 AMPK 则可同时降低细胞凋亡与自噬水平。
Macranthoside B (20 μM; 48 h) 可在孵育 48 h 后诱导人卵巢癌 A2780 细胞发生凋亡性细胞核形态改变。
Macranthoside B (10-20 μM) 可剂量依赖性地诱导表达 GFP-LC3 的人卵巢癌 A2780 细胞形成自噬点状结构。
Macranthoside B (15 μM; 48 h) 可激活 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中的自噬作用,增加 LC3B 斑点、自噬泡以及 LC3B II/P62 蛋白水平,同时抑制自噬流。
Macranthoside B (10 μM; 24-48 h) 可升高人卵巢癌 A2780 细胞内的 ROS 水平。
Macranthoside B (30-40 μM; 4 h) 可在人肝癌 HepG2 细胞中诱导具有早期凋亡特征的形态学改变,包括细胞变圆、染色质凝集和核固缩。
Macranthoside B (40 μM; 4 h) 可诱导人肝癌 HepG2 细胞发生凋亡,其中 39.02%的细胞进入早期凋亡阶段,13.45%的细胞进入晚期凋亡/坏死阶段。
Macranthoside B (30-40 μM; 4 h) 可通过线粒体介导的通路诱导人肝癌 HepG2 细胞发生凋亡,激活 caspase-9 和 caspase-3,切割 PARP,上调 Bax 蛋白表达,下调 Bcl-2 蛋白表达,并提高 Bax/Bcl-2 比值。
Macranthoside B (15 μM; 48 h) 处理 SKGT-4 食管腺癌 (AEG) 细胞可改变 1800 余种基因的表达,上调与氧化还原酶活性、铁死亡及自噬相关的通路。
Macranthoside B (10-15 μM; 48 h) 可诱导 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中脂质活性氧呈浓度依赖性累积,在 10 μM 和 15 μM 浓度下出现显著升高。
Macranthoside B (0-15 μM; 0-48 h) 以浓度和时间依赖的方式下调 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中的 GPX4 蛋白水平,分别将其水平降至对照组的 0.1 和 0.5。
Macranthoside B (0-15 μM; 0-48 h) 以浓度和时间依赖的方式上调 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中 NCOA4 和 FTH1 的蛋白水平,激活 NCOA4 介导的铁蛋白自噬。
Macranthoside B (0-15 μM; 48 h) 可抑制 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中的 NRF2,下调 NRF2 蛋白水平及其下游靶基因 HERC2 和 VAMP8,从而破坏铁稳态。
Macranthoside B (48 h) 会破坏 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中的铁稳态,显著提升细胞内 Fe2+水平。
Macranthoside B 可通过 ROS 过度生成及 MAPKs/JNK 通路激活,增强 Paclitaxel (HY-B0015) 诱导的人宫颈腺癌 HeLa 细胞凋亡。

Cell Viability Assay

Cell Line: Human ovarian carcinoma A2780 cells, human embryonic lung fibroblast HFL1 cells
Concentration: 1.25 μM, 2.5 μM, 5 μM, 1 μM, 20 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Inhibited A2780 cell viability in a concentration- and time-dependent manner, with IC50 values of 14.66 μM (24 h), 11.23 μM (48 h), 7.52 μM (72 h).
Exhibited IC50 values of 59.58 μM (24 h), 42.34 μM (48 h), 38.44 μM (72 h) in HFL1 cells, showing greater cytotoxicity toward tumor cells than normal cells.

Western Blot Analysis

Cell Line: human ovarian carcinoma A2780 cells
Concentration: 5 μM, 10 μM, 20 μM (48 h incubation); 10 μM (48 h incubation with inhibitor pretreatment or beclin 1 siRNA transfection)
Incubation Time: 48 h
Result: Increased levels of cleaved caspase-3, cleaved caspase-9, cleaved PARP, and LC3-II in a concentration-dependent manner at 5, 10, 20 μM for 48 h (cleaved caspase-3 levels relative to β-actin: 4.4, 20.0, 24.7; cleaved caspase-9: 10.5, 14.9, 23.5; cleaved PARP: 2.2, 3.4, 4.7; LC3-II: 3.4, 12.4, 24.9).
Decreased levels of cleaved caspase-3 (from 10.0 to 8.5), cleaved caspase-9 (from 2.0 to 1.8), cleaved PARP (from 1.0 to 0.5), and LC3-II (from 1.0 to 0.23) when cells were pretreated with 5 mM 3-methyladenine prior to 10 μM treatment.
Decreased LC3-II levels (from 1.0 to 0.19) and cleaved PARP levels (from 1.0 to 0.05) when cells were transfected with beclin 1 siRNA prior to 10 μM treatment.
Decreased levels of cleaved caspase-3 (from 2.1 to 0.2), cleaved caspase-9 (from 6.5 to 2.7), cleaved PARP (from 4.8 to 1.9), but increased LC3-II levels (from 2.0 to 3.8) when cells were pretreated with 10 μM Z-VAD-FMK prior to 10 μM treatment.
Decreased levels of cleaved caspase-3 (from 2.2 to 0.8), cleaved caspase-9 (from 1.7 to 1.5), cleaved PARP (from 1.6 to 0.7), and LC3-II (from 5.0 to 2.5) when cells were pretreated with 5 mM NAC prior to 10 μM treatment.
Decreased levels of cleaved caspase-3 (from 1.8 to 0.7) and LC3-II (from 1.6 to 0.7) when cells were pretreated with 10 μM Compound C prior to 10 μM treatment.

Western Blot Analysis

Cell Line: human ovarian carcinoma A2780 cells
Concentration: 5 μM, 10 μM, 20 μM (48 h incubation); 10 μM (48 h incubation with inhibitor pretreatment)
Incubation Time: 48 h
Result: Increased p-AMPK levels relative to β-actin (13.0, 18.9, 23.9) and decreased p-mTOR (0.9, 0.8, 0.6) and p-P70S6K (0.6, 0.4, 0.1) levels in a concentration-dependent manner at 5, 10, 20 μM for 48 h.
Decreased p-AMPK (from 2.4 to 1.1), p-mTOR (from 0.4 to 0.9), and p-P70S6K (from 0.5 to 1.0) levels when cells were pretreated with 5 mM NAC prior to 10 μM treatment.
Decreased p-AMPK (from 5.1 to 0.3), p-mTOR (from 0.3 to 0.9), and p-P70S6K (from 0.4 to 0.6) levels when cells were pretreated with 10 μM Compound C prior to 10 μM treatment.

Cell Viability Assay

Cell Line: human hepatoma HepG2, human gastric cancer MGC-803, human mammary adenocarcinoma MCF-7, human colonic carcinoma SW1116, human glioblastoma U251, rat glioma C6, mouse melanoma B16F1, mouse melanoma B16F10
Concentration: 2.55-80 μM; 4.25-48 μM (HepG2 cells)
Incubation Time: 48 h
Result: Inhibited HepG2 cell viability with inhibitory rates of 2.58%, 23.21%, 55.89%, 86.55%, and 98.14% at concentrations of 4.25, 7.08, 14.75, 23.04, and 48 μM respectively, with an IC50 of 10 μM.
Inhibited viability of all tested cell lines with IC50 values: MGC-803 (16 μM), MCF-7 (12 μM), SW1116 (14 μM), U251 (18 μM), C6 (14 μM), B16F1 (15 μM), and B16F10 (16 μM).

Apoptosis Analysis

Cell Line: Human hepatoma HepG2
Concentration: 40 μM
Incubation Time: 4 h
Result: Increased the percentage of early apoptotic cells to 39.02% and the percentage of late apoptotic/necrotic cells to 13.45%, compared to control cells.

Western Blot Analysis

Cell Line: human hepatoma HepG2
Concentration: 30 μM, 40 μM
Incubation Time: 4 h
Result: Increased cleaved PARP levels in a concentration-dependent manner.
Decreased procaspase-9 expression significantly, decreased procaspase-3 expression slightly, and increased levels of activated caspase-3 p17 and p12 subunits.
Increased Bax protein levels by 82% and 113% at 30 μM and 40 μM respectively, decreased Bcl-2 protein levels slightly, resulting in a notable increase in the Bax/Bcl-2 ratio.

Cell Viability Assay

Cell Line: normal gastric epithelial cell line (NGEC), adenocarcinoma of the esophagogastric junction (AEG) cell lines SKGT-4, OE-19, OE-33
Concentration: 0, 5, 10, 20, 30, 40 μM
Incubation Time: 24 h; 48 h
Result: Inhibited AEG cell viability in a concentration-dependent manner, with normal NGEC cells showing lower sensitivity.
Exhibited 24 h IC50 values of 9.51 μM (SKGT-4), 12.70 μM (OE-19), 10.98 μM (OE-33), and 22.80 μM (NGEC).
Exhibited 48 h IC50 values of 8.59 μM (SKGT-4), 8.47 μM (OE-19), 4.74 μM (OE-33), and 11.69 μM (NGEC).

Cell Proliferation Assay

Cell Line: adenocarcinoma of the esophagogastric junction (AEG) cell lines SKGT-4, OE-19
Concentration: 0, 8, 10 μM
Incubation Time: 24 h, followed by 15-20 days of drug-free growth
Result: Reduced the number of colonies in SKGT-4 and OE-19 cells in a concentration-dependent manner.
Caused statistically significant decreases (***p < 0.001) at both 8 μM and 10 μM compared to the control.

Cell Proliferation Assay

Cell Line: adenocarcinoma of the esophagogastric junction (AEG) cell lines SKGT-4, OE-19
Concentration: 0, 10, 15 μM
Incubation Time: 48 h
Result: Reduced the EDU-positive cell rate in SKGT-4 and OE-19 cells in a concentration-dependent manner.
Caused statistically significant decreases (**p < 0.01, ***p < 0.001) at 10 μM and 15 μM compared to the control.

Western Blot Analysis

...(内容过长已截断)
Cell Line: adenocarcinoma of the esophagogastric junction (AEG) cell lines SKGT-4, OE-19
Concentration: 0, 5, 10, 15 μM
体内研究
(In Vivo)

Macranthoside B (5 mg/kg;静脉注射;每 2 天 1 次;共 14 天) 在 HepG2 异种小鼠移植瘤模型中展现体内抗肿瘤活性,肿瘤生长抑制率达 53.29%。

Animal Model: Athymic BALB/cA nude mice (female, 35-40 days old, 18-22 g, subcutaneous implantation of HepG2 cells)
Dosage: 5 mg/kg
Administration: i.v.; every two days; 14 days
Result: Achieved 53.29% inhibition of tumor growth compared to vehicle control.
Significantly reduced relative tumor volume.
Lowered excised tumor weights compared to vehicle control.
性状 固体
颜色 White to off-white

化学信息

分子量 1075.24
分子式 C53H86O22
CAS No. 146100-02-9
别名 灰毡毛忍冬次皂苷乙

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 6 mg/mL (5.58 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (93.00 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.9300 mL4.6501 mL9.3002 mL23.2506 mL
5 mM0.1860 mL0.9300 mL1.8600 mL4.6501 mL
10 mM0.0930 mL0.4650 mL0.9300 mL2.3251 mL
15 mM0.0620 mL0.3100 mL0.6200 mL1.5500 mL
20 mM0.0465 mL0.2325 mL0.4650 mL1.1625 mL
25 mM0.0372 mL0.1860 mL0.3720 mL0.9300 mL
30 mM0.0310 mL0.1550 mL0.3100 mL0.7750 mL
40 mM0.0233 mL0.1163 mL0.2325 mL0.5813 mL
50 mM0.0186 mL0.0930 mL0.1860 mL0.4650 mL
60 mM0.0155 mL0.0775 mL0.1550 mL0.3875 mL
80 mM0.0116 mL0.0581 mL0.1163 mL0.2906 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础

  • 客服

    2851296953

    18923798467

    微信洽谈